Download PDF
Pharmacopsychiatry 2003; 36: 32-37
DOI: 10.1055/s-2003-40446
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Pharmacokinetics of Ginkgo biloba Extracts

A. Biber1
  • 1Dr. Willmar Schwabe GmbH & Co. KG, Research and Development, Karlsruhe
Further Information

Publication History

Publication Date:
07 July 2003 (online)

Also available at
    Permissions and Reprints

EGb 761® (definition see editorial) Ginkgo extract is produced by a validated production process. Its pharmacologically active constituents, flavonol glycosides and terpene lactones, are kept within a narrow range of 22 to 27 % and 5 to 7 %, respectively, by standardisation. The concentration of ginkgolic acids is below 5 ppm. The constant production process also maintains the concentrations of other constituents such as proanthocyanidins, carboxylic acids and non-flavone glycosides at a fairly constant level. In this article, we will summarise the data on the pharmacokinetics of flavonol glycosides and terpene lactones.

References

  • 1 Bhattaram V A, Graefe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of Herbal Medicinal Products.  Phytomedicine. 2002;  9(Suppl 3) 1-33
    PubMedSearch in Google Scholar
  • 2 Biber A, Koch E. Bioavailaility of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS.  Planta Med. 1999;  65 192-193
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Chatterjee S S, Jaggy H. Divergent pharmacological properties of different extracts of Ginkgo biloba. Poster 1st Int. Congr Ethnopharmacol 1990: p. 61
    Search in Google Scholar
  • 4 DeFeudis F V. Ginkgo biloba extract (EGb 761®). From chemistry to the clinic. Ullstein Medical Wiesbaden; 1998
    Search in Google Scholar
  • 5 De Smet P AGM, Brouwers J RBJ. Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.  Clin Pharmacokinet. 1997;  32 427-436
    CrossrefPubMedSearch in Google Scholar
  • 6 Drieu K. et al . Animal distribution and preliminary human kinetic studies of the flavonoid fraction of a standardized Ginkgo extract (EGb 761®).  Stud Org Chem. 1986;  23 351-359
    PubMedSearch in Google Scholar
  • 7 Fourtillan J B, Brisson A M, Girault J, Ingrand I, Decourt J P, Drieu K, Jouenne P, Biber A. Propriétés pharmacocinetiques du bilobalide et des ginkgolides A et B chez le sujet sain près administrations intraveineuses et orales d’extrait de ginkgo biloba (EGb 761®).  Therapie. 1995;  50 137-144
    PubMedSearch in Google Scholar
  • 8 Graefe E U, Derendorf H, Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans.  Int J Clin Pharmacol Ther. 1999;  37 219-233
    PubMedSearch in Google Scholar
  • 9 Graefe E U. et al . Pharmacokinetics and bioavailability of quercetin glycosides in humans.  J Clin Pharmacol. 2001;  41 492-499
    CrossrefPubMedSearch in Google Scholar
  • 10 Hollman P CH, Katan M B. Absorption, metabolism and health effects of dietary flavonoids in man.  Biomed Pharmacother. 1997;  51 305-310
    CrossrefPubMedSearch in Google Scholar
  • 11 Internal Report (1989) AD 846H. 
  • 12 Internal Report (1993) AD 969H. 
  • 13 Internal Report (1995) WS 0695/1. 
  • 14 Jaggy H. Die Inhaltsstoffe des Ginkgo-biloba-Extraktes EGb 761®.  Hämostaseologie. 1993;  13 7-10
    PubMedSearch in Google Scholar
  • 15 Masri M S, Booth A M, DeEds F. The metabolism and acid degradation of quercetin.  Arch Biochem Biophys. 1959;  85 284-286
    CrossrefPubMedSearch in Google Scholar
  • 16 Mauri P, Simonetti P, Gardana C, Minoggio M, Morazzoni P, Bombardelli E, Pietta P. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts.  Rapid Comm Mass Spect. 2001;  15 929-934
    CrossrefPubMedSearch in Google Scholar
  • 17 Moreau J P. et al .Absorption, distribution and excretion of tagged Ginkgo biloba leaf extract in the rat. Rökan Ginkgo biloba. Recent results in pharmacology and clinic. Fünfgeld (ed) Springer 1988: pp 37-45
    Search in Google Scholar
  • 18 Nieder M. Pharmakokinetik der Ginkgo-Flavonole im Plasma.  MMW. 1991;  133 S61
    PubMedSearch in Google Scholar
  • 19 Oliveira E J, Watson D G. In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes.  FEBS Lett. 2000;  471 1-6
    CrossrefPubMedSearch in Google Scholar
  • 20 Pietta P G. et al . Identification of flavonoid metabolites after oral administration to rats of a Ginkgo biloba extract.  J Chromatogr. 1995;  673 75-80
    PubMedSearch in Google Scholar
  • 21 Pietta P G. et al . Identification of Ginkgo biloba flavonol metabolites after oral administration to humans.  J Chromatogr. 1997;  693 249-255
    PubMedSearch in Google Scholar
  • 22 Sugiyama C. et al . Improvement of oral absorption of Ginkgo biloba extract by use of excipients.  Yakuzaigaku. 1998;  58 52-58
    PubMedSearch in Google Scholar
  • 23 Watanabe C M, Wolffram S, Ader P, Rimbach G, Packer L, Maguire J J, Schultz P G, Gohil K. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba.  PNAS. 2001;  98 6577-6580
    CrossrefPubMedSearch in Google Scholar
  • 24 Watson D G, Oliveira E J. Solid-phase extraction and GC/MS determination of kaempferol and quercetin in human urine after consumption of Ginkgo biloba tablets.  J Chromatogr. 1999;  723 203-210
    CrossrefPubMedSearch in Google Scholar
  • 25 Watson D G, Pitt A R. Analysis of flavonoids in tablets and urine by GC/MS and LC/MS.  Rapid Comm Mass Spec. 1998;  12 153-156
    CrossrefPubMedSearch in Google Scholar

Dr. Anton Biber

Abt. Forschung und Entwicklung

Dr. Willmar Schwabe GmbH & Co. KG

76227 Karlsruhe

Germany

Phone: +49 (721) 40 05-335

Fax: +49 (721) 40 05-557

Email: anton.biber@schwabe.de